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ABSTRACT
Total hip arthroplasty (THA) surgery for elderly people with 
multimorbidity increases the risk of serious health hazards 
including mortality. Whether such background morbidity 
reduces the clinical benefit is less clear.
Objective To evaluate how pre- existing health status, 
using multiple approaches, influences risks of, and quality 
of life benefits from, THA.
Setting Longitudinal record linkage study of a UK sample 
linking their primary care to their secondary care records.
Participants A total of 6682 patients were included, 
based on the recording of the diagnosis of hip 
osteoarthritis in a national primary care register and the 
recording of the receipt of THA in a national secondary 
care register.
Data were extracted from the primary care register on 
background health and morbidity status using five different 
constructs: Charlson Comorbidity Index, Electronic Frailty 
Index (eFI) and counts of comorbidity disorders (from list of 
17), prescribed medications and number of primary care 
visits prior to recording of THA.
Outcome measures (1) Postoperative complications and 
mortality; (2) postoperative hip pain and function using the 
Oxford Hip Score (OHS) and health- related quality of life 
using the EuroQoL (EQ)- 5D score.
Results Perioperative complication rate was 3.2% 
and mortality was 0.9%, both increased with worse 
preoperative health status although this relationship varied 
depending on the morbidity construct: the eFI showing 
the strongest relationship but number of visits having 
no predictive value. By contrast, the benefits were not 
reduced in those with worse preoperative health, and 
improvement in both OHS and EQ- 5D was observed in all 
the morbidity categories.
Conclusions Independent of preoperative morbidity, THA 
leads to similar substantial improvements in quality of life. 
These are offset by an increase in medical complications 
in some subgroups of patients with high morbidity, 
depending on the definition used. For most elderly people, 
their other health disorders should not be a barrier for THA.
BACKGROUND
National data on the short- term outcome 
from total hip arthroplasty (THA) demon-
strate a substantial improvement in quality 
of life.1 Most recipients are older adults: the 
median age, for example, in the UK countries 
reporting to the National Joint Registry is 69 
years.2
With increasing age, patients are increas-
ingly likely to develop multiple chronic 
health disorders (multimorbidity) with many 
patients described as frail.3–7 Such disorders 
increase the hazards from surgery8–10 and may 
also limit the benefits in quality of life.11–14 
There is in practice an inevitable selection 
process prior to performing surgery on older 
adults with multimorbidity, though there is 
no specific guidance on how these factors 
should influence surgical decision making, 
either in UK15 or USA.16
There are challenges in identifying a valid 
approach to measure the cumulative severity 
Strengths and limitations of this study
 ► National sample of older patients with newly re-
ported osteoarthritis of the hip who received a hip 
replacement.
 ► Multidimensional approach to assess their concur-
rent morbidity and health status prior to surgery 
from the primary care record.
 ► Linkage to surgical outcomes, including both haz-
ards (mortality and significant postoperative compli-
cations) and benefits (postoperative pain, function 
and quality of life) of THA.
 ► The challenge of using such routine data sources is 
to quantify the completeness of recording and accu-
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of all chronic health disorders.17 Simple counts of the 
presence of specific chronic diseases, or weighted instru-
ments (eg, Charlson score),18 typically focus on disor-
ders associated with the hazards especially mortality but 
exclude those that might impact on quality of life.19 In a 
companion paper to this one, we have demonstrated that 
in current practice in the UK, pre- existing health prob-
lems, even when only moderate in effect, do influence the 
likelihood and timing of THA. The question which then 
arose is whether this impact on acceptance for surgery 
appropriately reflects how far these health issues impact 
on surgical outcome.20
Our goal was to identify the impact of multimorbidity 
and frailty on the risks and benefits of THA. Our specific 
objectives were to assess, using a number of different 
approaches to scoring, how multimorbidity influenced 
the risks and benefits of elective total hip replacement 
for osteoarthritis. The former outcome was assessed by 
postoperative complications, length of stay and hospital 
readmission; and the latter assessed by patient- reported 
outcome measures (PROMs) covering pain, function and 
quality of life. To maximise the external validity, the study 
took advantage of the availability of English national data-
sets linking primary and secondary care.
METHODS
Summary of design
In a longitudinal record linkage study using a national 
database of primary care records, patients with a newly 
recorded diagnosis of hip osteoarthritis were identified. 
Linkage to a national database of secondary care records 
identified which individuals who had a THA; these indi-
viduals constituted the cohort of the study. The primary 
care record was interrogated to provide information on 
other health disorders and treatments were used to derive 
measures of pre- existing multimorbidity and health status 
at the time of surgery. This secondary care database also 
provided data on perioperative death and major compli-
cations as well as scores of patient outcome. The influence 
of the scores from these measures on mortality, inpatient 
complications and readmission within 90 days and post- 
operative PROMs were then calculated.
Data sources
We used the UK Clinical Practice Research Datalink 
(CPRD) which contains the primary care electronic 
medical records of approximately 4.4 million active 
patients and representative of the wider UK popula-
tion.21 Data are stored with Read codes for diseases that 
are cross- referenced to the International Classification of 
Diseases-10.
The Hospital Episode Statistics (HES) dataset contains 
all patient attendances at National Health Service (NHS) 
hospitals in England, and covers episodes of care. HES 
records patient demographic data, diagnoses and proce-
dures and is linked to national death certificate data 
and these data were provided anonymised. HES has also 
been linked since 2009 to the PROMs database gathering 
outcome data of NHS- funded THA, both preoperatively 
and at 6 months postoperatively.22
Study population
All patients in the CPRD with a Read code for hip osteo-
arthritis from 1 January 1995, until 31 March 2014, and 
aged ≥65 years at the time of diagnosis, were identified 
(ISAC protocol number 17_024R). The validation of 
those Read codes for hip osteoarthritis are described else-
where.23 Those patients who underwent elective primary 
THA, identified from HES, were included in the analysis. 
Operations were identified from the Classification of 
Surgical Operations and Procedures-4 codes.
The following measures of multimorbidity prior to the 
date of surgery were extracted from the accumulated 
primary care record. These were (1) Charlson Comor-
bidity Index (CCI)—developed to predict 1 year mortality 
based on the presence of specified chronic diseases,18 
(2) count of the 17 chronic diseases listed in the NHS 
Quality Outcomes Framework24, (3) electronic Frailty 
Index (eFI), a score based on the cumulative deficit 
model of frailty and validated against mortality, hospital-
isation and nursing home admission.25 We also used two 
measures of the burden of care associated with the pres-
ence of chronic conditions. Thus, within the 12 months 
prior to surgery, we extracted the number of (1) different 
prescribed medications and (2) primary care contacts for 
any reason.
Outcomes
All subjects had the following outcomes, in addition 
to death, extracted from the linked HES data within 
90 days of THA: venous thromboembolism, myocar-
dial infarction, stroke, anaemia, lower respiratory tract 
infection, urinary tract infection and wound infection. 
Also extracted were length of stay following surgery and 
readmission after discharge within 90 days. The national 
PROMs database provided data since 2009 on (1) Oxford 
Hip Score (OHS) as a measure of hip function and (2) 
EuroQoL (EQ)- 5D Index as a measure of quality of life at 6 
months postoperatively on all patients receiving a THA—
information on the appropriate interpretation of these 
scores is provided in the online supplemental appendix. 
Although all patients are invited to complete the PROMs 
questionnaires preoperatively and at 6 months postoper-
atively, completion rates vary. Further some respondents 
delay completing their postoperative scores beyond the 6 
months.22
Statistical analysis
The scores for each of the five measures of multimor-
bidity were split into four categories. The eFI has four 
categories defined by the developers: fit (0–4), mild frailty 
(5–8), moderate frailty (9–12) and severe frailty (>13). 
The actual CCI scores were used to split into categories 
of score of 0, 1, 2 and >3. Based on the distribution of the 
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split in categories of score of 0, 1, 2 and >3. The categories 
for the number of medications prescribed and of primary 
care visits were derived from the observed distributions 
of the actual data, aiming for equal- sized quarters: with 
medication counts divided into scores of 0–4, 5–7, 8–12 
and >13 and number of primary care visits into 0–7, 8–11, 
12–17 and >18. The lowest category for each score was 
used as the referent category in the analysis.
Logistic regression methods were used to calculate the 
unadjusted odds of a complication or readmission to 
hospital by multimorbidity category. Poisson regression 
methods were used to calculate the unadjusted differ-
ence in length of stay by multimorbidity category. Linear 
regression methods were used to calculate the differ-
ence in postoperative OHS and EQ- 5D score, adjusted 
for preoperative score, by multimorbidity category. All 
models were then adjusted for age at surgery, sex, region 
of the UK and calendar year of total hip replacement.
Patient and public Involvement
This research was funded by the National Institute for 
Health Research Research for Patient Benefit scheme 
which has an absolute requirement that there is patient 
and public involvement in all relevant stages of the 
research. The research question had been originally 
raised in a ‘Priority Setting Partnership for Priorities for 
Research in Hip and Knee Arthroplasty’ and this was 
followed by a survey of members of the Keele Patient 
and Public Involvement panel: Research Users Group 
(RUG). We then tested the suggested questions with 
the group and received very positive feedback. One of 
the RUG members (CW), herself a patient with direct 
experience of the target of the research, then became 
an active member of the research team, participated in 
all the meetings and advised on the design including 
the questions that should be asked during the analysis 
stage. As part of the dissemination phase, Keele Patient 
and Public Involvement group organised a round- table 
event attended by the lead authors where the results were 
discussed and guidance given on how those members of 
the public who were present wished to see disseminated.
RESULTS
Baseline data
The demographic characteristics of the study participants 
are shown in table 1. There were 6682 patients with a 
code for hip osteoarthritis on the primary care record 
who after linkage to the HES data, had a THA within the 
follow- up period from April 1997 to March 2014. The 
mean age at surgery was 76 years (SD 6).
Preoperative scores for the four multimorbidity 
measures derived are shown in table 2. Only 20% had 
a CCI >1 perhaps reflecting the selection of patients for 
surgery. Based on the eFI classification, 34% were clas-
sified as ‘mildly frail’ and 6.5% ‘moderately or severely 
frail’. Around 1 in 6 had three or more chronic disorders 
recorded. Over 40% had been prescribed at least eight 
medications, and a similar proportion had >12 primary 
care visits, in the previous 12 months.
Outcomes
Data on complications, length of stay and readmission 
to hospital were available on all patients (as linkage to 
HES was a criterion for study entry). As mentioned above, 
data on PROMs were only available on a subset of patients 
who completed the questionnaires (figure 1). In total, 
preoperative and postoperative OHS were available on 
1402 patients, and preoperative and postoperative EQ- 5D 
Index were available on 1285 patients. As a test of bias, we 
compared the multimorbidity measures between those 
with and without PROMs (online supplemental table 1) 
which, while showing no substantive shifts across all the 
measures, found those who did not provide PROMs were 
more likely to have worse multimorbidity and also reside 
in more socioeconomically deprived areas.
 
Association between multimorbidity measures and adverse 
outcomes
In all, 216 (3.2%) patients suffered a postoperative 
complication including thromboembolism, myocardial 
infarction, urine and respiratory infections and wound 
infection, and 57 (0.9%) patients died, within 90 days 
of surgery (table 3). The rate of all- cause readmission to 
hospital within 90 days of surgery was 11%.
Table 1 Demographic characteristics of cohort
Gender N (%)
  Female 4090 (61.2)
Age (years)
  65–69 1294 (19.4)
  70–74 1976 (29.6)
  75–79 1736 (26.0)
  80–84 1095 (16.4)
  85–89 465 (7.0)
  >90 116 (1.7)
Body mass index
  Underweight (<18.5) 54 (1.0)
  Normal (18.5–24.9) 1615 (28.8)
  Overweight (25–29.9) 2444 (43.6)
  Obese (>30) 1497 (26.7)
  Missing 1072
Index of multiple deprivation
  1 (Affluent) 1076 (25.5)
  2 1718 (25.7)
  3 1539 (23.0)
  4 1144 (17.1)
  5 (Deprived) 573 (8.6)
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The impact of multimorbidity scores across all these 
medical complications are shown in table 4. The overall 
adverse event rate was only modestly increased with 
increasing levels of multimorbidity relative to the lowest 
scoring group. These increases in risks were attenu-
ated after adjustment for age and the other possible 
confounders. Those in highest frailty group were the 
most predictive of a medical complication. By contrast, 
the other measures of multimorbidity were only weakly 
predictive; with some measures such as the number of 
primary care visits showing no trend. We analysed the indi-
vidual complications separately (data not shown). The 
numbers with any of the individual complications were 
small but there were no substantial difference between 
the risks of individual complications in their relationship 
with the multimorbidity scores.
The data on mortality are shown in table 5. The 
mortality risk in the least healthy stratum ranged from 
0.7% for the group with the highest number of primary 
Table 2 Baseline data on measures of preoperative health 
status (multimorbidity, frailty and morbidity burden)
Charlson Comorbidity Index
  0 4490 (67.2)
  1 682 (10.2)
  2 880 (13.2)
  >3 630 (9.4)
Electronic Frailty Index
  0–4 4184 (62.6)
  5–8 2064 (30.9)
  9–12 393 (5.9)
  >13 41 (0.6)
No. of comorbid diseases
  0 1901 (28.5)
  1 2286 (34.2)
  2 1430 (21.4)
  >3 1065 (15.9)
No. of medications prescribed
  0–4 1963 (29.4)
  5–7 1832 (27.4)
  8–12 1992 (29.8)
  >13 895 (13.4)
No. of contacts with primary care
  0–7 2167 (32.4)
  8–11 1598 (23.9)
  12–17 1528 (22.9)
  >18 1389 (20.8)
Figure 1 Flow chart of data available for analysis. HES, Hospital Episode Statistics; PROMs, patient- reported outcome 
measures.
Table 3 Complications, length of stay and readmission to 
hospital within 90 days
N (%)
Any medical complication* 216 (3.2)
Death 57 (0.9)
Myocardial infarction 20 (0.3)
Venous thromboembolism 54 (0.8)
Stroke 8 (0.1)
Anaemia 12 (0.2)
Respiratory tract infection 28 (0.4)
Urinary tract infection 12 (0.2)
Wound infection 37 (0.6)
Length of stay (median, IQR) 6 (4–9)
Readmission to hospital 727 (10.9)
*Any medical complication includes death, myocardial infarction, 
venous thromboembolism, stroke, anaemia, respiratory tract 
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care contacts to 2.3% for those with an eFI of ≥9. There 
was an inconsistent association between death and 
Charlson score but the number of events in those with 
a Charlson score >2 were too small for useful analysis. 
Neither the groups with the number of prescribed medi-
cations nor of primary care contacts predicted mortality. 
The measure with the greatest predictive power of death 
was the eFI. After adjustment for age and gender, those 
in the two highest frailty groups had a 2.5- fold increased 
mortality risk. The overall number of deaths though was 
modest and the resulting small numbers when stratified 
by preoperative morbidity category, limits the precision of 
these estimates.
The impact of multimorbidity scores on length of stay 
were also analysed. Detailed data are not shown but in 
brief for all the multimorbidity measures, apart from the 
eFI, there was no impact on length of stay. The median 
length of stays in the lowest and highest categories of 
multimorbidity were: 6 and 7 days for Charlson score, 
6 and 8 days for eFI score, 6 and 7 days for the count of 
chronic diseases, and 6 and 7 days for the count of medi-
cations prescribed.
We have also examined the impact of these preopera-
tive health measures on two indirect measures of compli-
cations: readmission rates and length of stay (LOS). 
Overall, there were 786 patients readmitted for any reason 
over the next 90 days. Risks were related to level of preop-
erative health with those in the worst health categories 
having a twofold increased risk compared with those in 
in the healthiest group. The results were broadly similar 
independent of the scoring approach (online supple-
mental table 2). As regards LOS, the differences between 
grades of prior ill health were modest, with the median 
and interquartile ranges almost identical. The eFI was a 
slight outlier where those in the highest two categories 
had a median LOS 2 days higher than those with lesser 
frailty (online supplemental table 3).
Table 4 Association between preoperative morbidity status and 90- day medical complications
No. at risk Events % Events Unadjusted OR Adjusted OR*
Charlson Comorbidity Index
  0 4490 120 2.67 Ref Ref
  1 682 27 3.96 1.50 (0.98 to 2.30) 1.43 (0.93 to 2.20)
  2 880 43 4.89 1.87 (1.31 to 2.67) 1.78 (1.24 to 2.56)
  >3 630 26 4.13 1.57 (1.02 to 2.42) 1.46 (0.94 to 2.26)
Electronic Frailty Index
  0–4 4184 112 2.68 Ref Ref
  5–8 2064 75 3.63 1.37 (1.02 to 1.85) 1.31 (0.96 to 1.78)
  9–12 393 26 6.62 2.58 (1.66 to 4.00) 2.26 (1.42 to 3.62)
  >13 41 <5†
Comorbid diseases
  0 1901 53 2.79 Ref Ref
  1 2286 53 2.32 0.83 (0.56 to 1.22) 0.80 (0.54 to 1.18)
  2 1430 57 3.99 1.45 (0.99 to 2.12) 1.41 (0.96 to 2.08)
  >3 1065 53 4.98 1.83 (1.24 to 2.69) 1.74 (1.16 to 2.61)
Prescriptions
  0–4 1963 49 3.09 Ref Ref
  5–7 1832 55 2.75 1.21 (0.82 to 1.79) 1.17 (0.79 to 1.73)
  8–12 1992 68 3.53 1.38 (0.95 to 2.00) 1.28 (0.88 to 1.87)
  >13 895 33 3.67 2.02 (1.33 to 3.06) 1.85 (1.21 to 2.83)
Primary care contacts
  0–7 2167 67 3.09 Ref Ref
  8–11 1598 44 2.75 0.89 (0.60 to 1.31) 0.85 (0.58 to 1.25)
  12–17 1528 54 3.53 1.15 (0.80 to 1.65) 1.09 (0.76 to 1.58)
  >18 1389 51 3.67 1.19 (0.82 to 1.73) 1.07 (0.74 to 1.57)
  Total 6682 216
*Adjusted for age, gender, region and calendar year of surgery.
†The rules set for approval of use of CPRD data require that authors are not allowed to indicate the number of events in any category if 
they are <5.
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Association between multimorbidity measures and quality of 
life
Across all patients, there was an overall marked improve-
ment in both the specific (OHS) and the generic (EQ- 
5D) patient outcomes. The summary outcome data are 
shown in table 6, confirming substantial improvement 
at 6 months in both the OHS and EQ- 5D across the 
population studied. The mean improvement in OHS of 
around 20 did not vary importantly between the different 
levels of any of the approaches to assessing the preoper-
ative morbidity (table 7). For each of our measures of 
multimorbidity, the preoperative OHS was lower with 
increasing score. What was of note was the similarity in 
the relative improvement in the postoperative OHS seen 
across the board for all measures of multimorbidity. Typi-
cally mean preoperative scores in the mid- to- late teens 
reached scores in the high 30s and 40s; the highest score 
achievable is 48. Thus, surgery led to a marked improve-
ment, not attenuated by the severity of the preoperative 
general health.
A similar analysis was undertaken on EQ- 5D (table 8). 
As expected, those with a higher preoperative morbidity 
had a lower preoperative EQ- 5D, reflecting the impact 
of the patients’ other comorbid disorders on their 
overall quality of life. However, the 6- month incremental 
improvement in EQ- 5D was almost identical across all 
categories of multimorbidity, independent of the method 
of multimorbidity scoring. The actual EQ- 5D scores were 
Table 5 Association between preoperative multimorbidity and 90- day mortality
No. at risk Events % Events Unadjusted OR Adjusted OR*
Charlson Comorbidity Index
  0 4490 32 0.71 Ref Ref
  1 682 6 0.88 1.24 (0.52 to 2.97) 1.09 (0.45 to 2.65)
  2 880 13 1.48 2.09 (1.09 to 4.00) 1.85 (0.95 to 3.60)
  >3 630 6 0.95 1.34 (0.56 to 3.22) 1.12 (0.46 to 2.73)
Electronic Frailty Index
  0–4 4184 27 0.65 Ref Ref
  5–8 2064 20 0.97 1.51 (0.84 to 2.69) 1.33 (0.72 to 2.44)
  9–12 393 10 2.54 4.02 (1.93 to 8.37) 2.78 (1.24 to 6.23)
  >13 41 0 0 – –
Comorbid diseases
  0 1901 14 0.74 Ref Ref
  1 2286 10 0.44 0.59 (0.26 to 1.34) 0.58 (0.26 to 1.33)
  2 1430 16 1.12 1.53 (0.74 to 3.14) 1.50 (0.71 to 3.16)
  >3 1065 17 1.60 2.19 (1.07 to 4.45) 2.12 (0.99 to 4.51)
Prescriptions
  0–4 1963 11 0.56 Ref Ref
  5–7 1832 19 1.04 1.86 (0.88 to 3.92) 1.80 (0.85 to 3.82)
  8–12 1992 18 0.90 1.62 (0.76 to 3.43) 1.39 (0.64 to 2.98)
  >13 895 9 1.01 1.80 (0.74 to 4.37) 1.51 (0.61 to 3.75)
Primary care contacts
  0–7 2167 20 0.92 Ref Ref
  8–11 1598 13 0.81 0.88 (0.44 to 1.78) 0.81 (0.40 to 1.65)
  12–17 1528 15 0.98 1.06 (0.54 to 2.09) 0.90 (0.45 to 1.78)
  >18 1389 9 0.65 0.70 (0.32 to 1.54) 0.53 (0.24 to 1.19)
  Total 6682 57
*Adjusted for age, gender, region and calendar year of surgery.
Table 6 Patient- reported outcome measures
N Mean (SD)
Oxford Hip Score
  Preoperative 1460 17.9 (7.9)
  Postoperative 1416 39.3 (8.2)
  Change 1402 21.3 (9.7)
EuroQoL- 5D Index
  Preoperative 1380 0.35 (0.31)
  Postoperative 1367 0.80 (0.23)
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moderately lower in the highest categories of multimor-
bidity but the relative improvement was the same. Regres-
sion analyses, both unadjusted and adjusted for age and 
gender showed that the postoperative scores, adjusted for 
the preoperative scores, were not importantly different 
(see online supplemental appendix 1) for any of the 
multimorbidity scores compared with the lowest score in 
each grading system.
DISCUSSION
Although previous studies have demonstrated a link 
between same indices of serious morbidity, such as the 
Charlson score and subsequent long- term mortality19, this 
is the first study to comprehensively assess the impact of 
multiple approaches to preoperative health measures, on 
the broad range of risks and benefits of THA. We have 
demonstrated that there is a link between worse preop-
erative health status with risk of death and of clinically 
significant medical event rates, although the size and 
the steepness of any trend varied between the different 
approaches to assessing health. There is no single obvious 
measure which captures all the relevant dimensions. Of 
interest was that these approaches in general did not 
yield consistent differences in these results, although the 
number of primary care contacts was ‘an outlier’ in this 
respect and would not appear to be useful as a measure 
of health status.
The other important result was that THA is associated 
with a substantial improvement in quality of life, indepen-
dent of level of pre- existing multimorbidity. Indeed, this 
was true for all the approaches used to assess health. This 
consistency in the level of benefit is thus in contrast to the 
variable impact between these approaches on complica-
tions of surgery.
There are some limitations of these data. First, we have 
not considered the impact of different types of surgery 
and anaesthesia together with other prophylactic inter-
ventions to reduce the hazards from surgery in this group 
of patients. For example, the routine use of the use of 
thromboprophylaxis should reduce the risk of throm-
boembolism even in those with the highest multimor-
bidity. Such interventions would not, though, explain the 
Table 7 Postoperative Oxford Hip Score by multimorbidity
No. Preoperative Postoperative Change Unadjusted difference Adjusted*
Charlson Comorbidity Index
  0 960 18.5 (8.0) 39.9 (8.0) 21.4 (9.6) Ref Ref
  1 113 17.6 (8.4) 37.5 (9.7) 20.1 (10.5) −2.0 (−3.6 to –0.5) −2.0 (−3.6 to –0.5)
  2 199 16.0 (7.5) 37.8 (8.3) 21.9 (9.4) −1.4 (−2.6 to –0.2) −1.0 (−2.2 to 0.2)
  >3 130 16.8 (7.1) 38.5 (8.1) 21.5 (10.0) −1.15 (−2.5 to 0.4) −0.60 (−2.0 to 0.8)
EFI
  0–4 798 18.8 (7.9) 40.7 (7.5) 21.8 (9.4) Ref Ref
  5–8 511 17.3 (7.9) 37.7 (8.8) 20.5 (10.2) −2.5 (−3.4 to –1.7) −2.0 (−2.9 to –1.2)
  9–12 86 14.6 (7.0) 35.8 (8.1) 21.4 (8.8) −3.6 (−5.4 to –1.9) −2.9 (−4.7 to –1.1)
  >13 7 14.7 (8.2) 39.1 (10.4) 24.4 (8.7) −0.45 (−6.2 to 5.3) 1.0 (−4.8 to 6.7)
Comorbid diseases
  0 358 18.9 (7.8) 40.7 (7.9) 21.7 (9.9) Ref Ref
  1 481 18.6 (8.1) 39.9 (7.9) 21.3 (9.6) −0.7 (−1.8 to 0.4) −0.4 (−1.5 to 0.6)
  2 324 17.6 (7.9) 38.7 (8.2) 21.0 (9.6) −1.6 (−2.8 to −0.4) −1.2 (−2.3 to 0.1)
  >3 239 15.7 (7.5) 36.9 (8.9) 21.2 (9.7) −3.0 (−4.3 to –1.7) −2.3 (−3.6 to –1.0)
Prescriptions
  0–4 407 19.9 (7.4) 41.4 (7.1) 21.4 (9.3) Ref Ref
  5–7 383 19.4 (8.1) 40.4 (7.4) 20.9 (9.5) −0.8 (−1.9 to 0.3) −0.5 (−1.6 to 0.6)
  8–12 406 16.6 (7.7) 38.2 (8.5) 21.7 (9.9) −2.3 (−3.4 to –1.2) −2.0 (−3.0 to –0.9)
  >13 206 14.1 (7.3) 35.4 (9.2) 21.3 (10.3) −4.6 (−5.9 to –3.2) −4.0 (−5.3 to –2.4)
Primary care contacts
  0–7 2167 18.9 (7.8) 39.9 (7.8) 21.0 (8.9) Ref Ref
  8–11 1598 18.3 (8.1) 40.1 (7.8) 21.7 (10.0) 0.3 (−0.8 to 1.5) 0.6 (−0.6 to 1.7)
  12–17 1528 17.8 (7.8) 39.4 (8.1) 21.7 (9.9) −0.1 (−1.2 to 1.0) 0.4 (−0.7 to 1.5)
  >18 1389 16.1 (9.1) 37.2 (9.2) 21.1 (10.3) −2.0 (−3.2 to –0.8) −1.5 (−2.7 to –0.3)
  Total 1402 1460 1416 1402
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observation that improvement in patient outcome is not 
materially affected by pre- existing morbidity.
Second, inevitably in studies of this type, there is a reli-
ance on the completeness, and quality diagnostic accu-
racy in the data sets available. We relied on the quality 
of the CPRD to provide information on the diagnosis of 
osteoarthritis of the hip and of the multimorbidity scores. 
As regards the former, a validation study using radiolog-
ical and clinical information from a subsample of this 
cohort, described elsewhere, confirmed the diagnosis of 
hip osteoarthritis in 80%.20 As regards the latter there are 
many reports on the validity of the national datasets used 
for deriving multimorbidity information.21 26
There is also a similar reliance on the quality of the 
outcome data from HES. Although data from HES are 
widely accepted as being sufficiently valid27 we were 
concerned that this data source captured a high propor-
tion of these relevant outcome events with minimal 
misclassification. As a test of the quality of the outcomes 
data, we therefore compared our results on postoper-
ative hazard rates with other published data to deter-
mine whether such rates were broadly similar. There are 
limitations in such comparisons, but this analysis suggested 
that the observed rates of clinically significant events in 
the population studied did accord with those published 
from other countries. For example, our VTE incidence 
was 2.1%, published population data suggest a range 
of 0.7%–3.9%.28–30 Similar comparisons for MI were as 
follows: this study 0.4%, literature 0.4%–0.6%31–33; wound 
infection present study 1.7%, literature 2.2%–2.9%.34
Readmission rate is also useful as an indirect measure 
of complications. Indeed, the impact of both being in the 
most frail category of eFI and number of prescriptions 
was similar on the rates of both readmissions (online 
supplemental table 1) to that seen on complications 
(table 4). The agreement was less observed with primary 
care contacts which reflects health seeking behaviours as 
well as morbidity.
Preoperative health status had little effect on LOS, 
perhaps surprisingly but this may be complex to unpack 
given differences in anaesthetic procedure. We specif-
ically studied multiple ways of measuring pre- existing 
morbidity and its impact on health, given there is no 
single ‘best way of measuring morbidity, and all such 
Table 8 Postoperative EuroQoL- 5D by multimorbidity
No. Preoperative Postoperative Change Unadjusted difference Adjusted difference*
Charlson Comorbidity Index
  0 880 0.37 (0.31) 0.82 (0.22) 0.45 (0.34) Ref Ref
  1 108 0.33 (0.32) 0.77 (0.25) 0.44 (0.33) −0.036 (−0.080 to 0.007) −0.037 (−0.080 to 0.007)
  2 178 0.29 (0.31) 0.76 (0.22) 0.48 (0.34) −0.038 (−0.073 to −0.002) −0.028 (−0.064 to 0.007)
  >3 119 0.33 (0.29) 0.74 (0.24) 0.40 (0.33) −0.072 (−0.114 to −0.030) −0.060 (−0.102 to −0.018)
Electronic Frailty Index
  0–4 735 0.39 (0.31) 0.83 (0.20) 0.45 (0.33) Ref Ref
  5–8 464 0.32 (0.31) 0.76 (0.23) 0.45 (0.36) −0.059 (−0.084 to −0.033) −0.048 (−0.073 to −0.022)
  9–12 79 0.20 (0.29) 0.69 (0.28) 0.47 (0.34) −0.141 (−0.192 to −0.090) −0.126 (−0.178 to −0.074)
  >13 7 0.20 (0.35) 0.78 (0.35) 0.59 (0.32) −0.021 (−0.184 to 0.141) .004 (−0.157 to 0.166)
Comorbid dis
  0 330 0.39 (0.31) 0.85 (0.19) 0.46 (0.34) Ref Ref
  1 429 0.38 (0.31) 0.81 (0.20) 0.43 (0.32) −0.037 (−0.068 to −0.005) −0.030 (−0.062 to 0.001)
  2 306 0.33 (0.31) 0.78 (0.23) 0.45 (0.35) −0.060 (−0.094 to −0.026) −0.049 (−0.084 to −0.015)
  >3 220 0.26 (0.32) 0.71 (0.28) 0.45 (0.36) −0.122 (−0.159 to −0.084) −0.105 (−0.143 to −0.067)
Prescriptions
  0–4 378 0.42 (0.30) 0.85 (0.20) 0.44 (0.34) Ref Ref
  5–7 351 0.41 (0.30) 0.83 (0.20) 0.42 (0.32) −0.023 (−0.055 to 0.008) −0.062 (−0.062 to 0.001)
  8–12 372 0.30 (0.30) 0.77 (0.22) 0.47 (0.34) −0.071 (−0.103 to −0.040) −0.084 (−0.084 to −0.015)
  >13 184 0.19 (0.31) 0.69 (0.28) 0.50 (0.37) −0.139 (−0.178 to −0.099) −0.143 (−0.143 to −0.067)
Primary care contacts
  0–7 2167 0.39 (0.31) 0.82 (0.22) 0.44 (0.33) Ref Ref
  8–11 1598 0.36 (0.30) 0.83 (0.21) 0.46 (0.34) 0.003 (−0.029 to 0.036) .007 (−0.025 to 0.039)
  12–17 1528 0.36 (0.31) 0.80 (0.21) 0.44 (0.35) −0.018 (−0.049 to 0.013) −0.010 (−0.042 to 0.021)
  >18 1389 0.26 (0.32) 0.72 (0.26) 0.47 (0.35) −0.079 (−0.114 to −0.044) −0.070 (−0.106 to −0.034)
  Total 1285 1380 1367 1285
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scores are measures of an underlying, but hard- to- 
measure, construct. This resulted in multiple estimates 
of effect. We were not attempting to prove statistical 
significance by finding one or more measure that was 
useful. More, by using multiple options, we covered as 
far as possible the different suggested approaches to 
ascertaining multimorbidity. A detailed statistical analysis 
identifying the concordance between these measures was 
outside the scope of this study, we were not attempting to 
pool the data to provide a single measure of health. Obvi-
ously, these different measures will overlap in the patients 
classified. One of the strengths of this study was that the 
measures did not yield always similar relationships, espe-
cially with the risk studied. This is not, however, surprising 
as they were measuring different constructs. Despite such 
differences, none of the scoring systems had substantial 
effects on outcome. One construct of patient health that 
was not collected from these routine data is the patient’s 
perception of their own status. Others have shown for 
example that EQ- 5D, measured prior to surgery, is asso-
ciated with longer term mortality.35 One problem with 
using such measures measured at a single point of time is 
that they fluctuate more than the longer interval used in 
this study to capture these primary- care recorded events.
There are other variables that might be confounders 
which have not been addressed in the analyses presented 
which include socioeconomic status, body mass index 
and cigarette smoking. We specifically did not adjust for 
the possible confounding effects of these variables in part 
because of the quality and completeness of the data. More 
importantly, we were concerned that the effect of these 
variables would most likely be mediated by their associa-
tion with other comorbid disorders and interpretation of 
such adjusted results would be difficult.
The data on benefits were only collected at 6 months 
postoperatively. We cannot comment on the long- term 
impact of these preoperative measures on quality of life. 
This is not without challenges given the increasing likeli-
hood over time that there may be other changes in health 
that will impact on overall benefit.
Finally, the patients studied in this cohort were inevi-
tably those who underwent surgery. Our comparisons 
therefore were between those in the different morbidity 
categories for whom a decision had been made that 
surgery was appropriate. We could not address whether, 
within each such category, there were selective differences 
in surgical decision making that might be associated 
with the outcomes measured. One reasonable unmea-
sured confounder relates to prior perception of benefit. 
Thus, the individuals with major health issues who agree 
to surgery might have a higher expectation of outcome. 
Such individuals might then score higher on their self- 
reported outcomes, than otherwise similar patients who 
did not have surgery.
This study aimed to investigate the influence of 
common long- term disorders in the population and their 
influence on the risks and benefits from hip surgery. It 
is accepted that those at greatest risk from anaesthesia 
and major surgery should be identified, especially for an 
elective procedure such as THA. Preoperative morbidity 
does increase the mortality risk.8 10 36 By contrast, there 
are very little data on how the co- existing health prob-
lems affect the clinical benefits. Indeed, we have shown 
in a recent analysis that those patients who have under-
gone THA in the highest American Society of Anesthe-
siologists (ASA)37 grade (≥III) are at increased risk of 
revision surgery,38 a result that is not unexpected. ASA 
grades while routinely collected for example in national 
joint registers, are not extractable from primary care data 
systems. The underlying concern behind undertaking 
the current study was that, especially in older individuals, 
the lack of an evidence base weighing up the risks and 
benefits from surgery, leads to patients, their families and 
healthcare professionals, accepting that surgery should 
be avoided. The current study suggests that the increased 
risks are modest but the benefits remain substantial.
As part of the study design, we have been able to 
examine a number of different approaches to assessing 
multimorbidity in primary care patients. Indeed, that 
setting with the complete medical record provides the 
only practical one for scoring multimorbidity of patients 
in clinical practice. The eFI, a recently developed tool 
for assessing frailty from the primary care record,25 is 
achieving widespread usage in the UK and elsewhere for 
classifying frailty in elderly patients. High eFI scores are 
associated with substantial increased risks of mortality, 
unplanned hospital admission and the need for long 
term care.25 It is thus interesting that within the current 
dataset the differences in eFI class were, if anything more 
predictive of outcomes than the other approaches. It 
should be noted though that the proportion of the popu-
lation selected for surgery in the highest eFI category was 
small. Furthermore, even a high eFI class on our data, 
should not, of itself, be a barrier to surgery.
We conclude that in older patients requiring a hip 
replacement, unless they are in the small group whose 
anaesthetic risk precludes safe surgery, there is no 
evidence that their other long- term disorders should be a 
barrier to this life- changing elective procedure.
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